Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol Versus FOSTER® in Patients With Asthma.
Lunan Better Pharmaceutical Co., LTD.
416 participants
Jun 8, 2026
INTERVENTIONAL
Conditions
Summary
A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with asthma. The purpose of this study is to compare the efficacy and safety of the Beclomethasone Dipropionate and Formoterol Fumarate inhalation aerosol (manufactured by Lunan Better Pharmaceutical Co., Ltd.) with FOSTER® in the treatment of patients with asthma.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
Beclometasone Dipropionate and Formoterol Inhalation Aerosol was administered by oral inhalation at a dose of 2 actuations twice daily (morning and evening) for 4 consecutive weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07768891